|
SV2007002227A
(es)
*
|
2004-09-10 |
2007-03-20 |
Wyeth Corp |
Anticuerpos anti-5t4 humanizados y conjugados anticuerpo anti-5t4/calicheamicina ref. 040000-0317637
|
|
US8008453B2
(en)
|
2005-08-12 |
2011-08-30 |
Amgen Inc. |
Modified Fc molecules
|
|
EP1790664A1
(en)
*
|
2005-11-24 |
2007-05-30 |
Ganymed Pharmaceuticals AG |
Monoclonal antibodies against claudin-18 for treatment of cancer
|
|
EP1957097A1
(en)
*
|
2005-12-06 |
2008-08-20 |
Wyeth a Corporation of the State of Delaware |
Interleukin-11 compositions and methods of use
|
|
DK2368914T3
(en)
|
2006-03-10 |
2019-03-04 |
Wyeth Llc |
Anti-5T4 antibodies and uses thereof
|
|
CY1112212T1
(el)
*
|
2008-04-24 |
2015-12-09 |
Immatics Biotechnologies Gmbh |
Νεα σκευασματα πεπτιδιων που σχετιζονται με ογκους τα οποια συνδεονται σε μορια του αντιγονου ανθρωπινων λευκοκυτταρων (hla) ταξης i ή ii για εμβολια
|
|
EP2113253B1
(en)
*
|
2008-04-30 |
2010-03-31 |
Immatics Biotechnologies GmbH |
Novel formulations of tumour-associated peptides binding to human leukocyte antigen (HLA) class I or II molecules for vaccines
|
|
AR076284A1
(es)
|
2009-04-29 |
2011-06-01 |
Bayer Schering Pharma Ag |
Inmunoconjugados de antimesotelina y usos de los mismos
|
|
FR2947269B1
(fr)
|
2009-06-29 |
2013-01-18 |
Sanofi Aventis |
Nouveaux composes anticancereux
|
|
EP2493506B1
(en)
*
|
2009-10-30 |
2019-04-10 |
Janssen Biotech, Inc. |
Il-17a antagonists
|
|
EP2637692A4
(en)
|
2010-11-12 |
2014-09-10 |
Scott & White Healthcare |
ANTIBODIES TO THE ENDOTHELIAL TUMOR MARKER 8
|
|
US9540443B2
(en)
|
2011-01-26 |
2017-01-10 |
Kolltan Pharmaceuticals, Inc. |
Anti-kit antibodies
|
|
MX393973B
(es)
|
2011-05-08 |
2025-03-24 |
Legochem Biosciences Inc |
Conjugados de proteína-agente activo y método para su preparación.
|
|
RU2011132483A
(ru)
*
|
2011-08-02 |
2013-02-10 |
Елена Александровна Моренко |
Биологически активный продукт для применения в ветеринарии и животноводстве, способ его получения и способы повышения выживаемости, стимуляции роста, иммуностимуляции и повышения общей неспецифической резистентности организма сельскохозяйственных животных
|
|
CN110078827A
(zh)
|
2012-04-27 |
2019-08-02 |
西托姆克斯治疗公司 |
结合表皮生长因子受体的可活化的抗体其使用方法
|
|
US20130309223A1
(en)
|
2012-05-18 |
2013-11-21 |
Seattle Genetics, Inc. |
CD33 Antibodies And Use Of Same To Treat Cancer
|
|
HK1210192A1
(en)
|
2012-07-19 |
2016-04-15 |
Alethia Biotherapeutics Inc. |
Anti-siglec-15 antibodies
|
|
NZ630363A
(en)
|
2012-07-25 |
2018-09-28 |
Celldex Therapeutics Inc |
Anti-kit antibodies and uses thereof
|
|
JP6847388B2
(ja)
|
2013-03-15 |
2021-03-31 |
レゲネロン ファーマシューティカルス，インコーポレーテッド |
生物活性分子、そのコンジュゲート、及び治療用途
|
|
BR112016004023A2
(pt)
|
2013-08-26 |
2022-11-16 |
Regeneron Pharma |
Composição, métodos para preparar uma composição e para tratar uma doença, e, composto
|
|
WO2015066279A2
(en)
|
2013-10-30 |
2015-05-07 |
Cytomx Therapeutics, Inc. |
Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
|
|
WO2015089283A1
(en)
|
2013-12-11 |
2015-06-18 |
Cytomx Therapeutics, Inc. |
Antibodies that bind activatable antibodies and methods of use thereof
|
|
JP6632984B2
(ja)
|
2014-03-11 |
2020-01-22 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
抗ＥＧＦＲｖＩＩＩ抗体およびその使用
|
|
BR112017020149A8
(pt)
|
2015-03-27 |
2023-05-02 |
Regeneron Pharma |
Derivados de maitansinoide, conjugados dos mesmos e métodos de uso
|
|
CA2990206A1
(en)
*
|
2015-06-29 |
2017-01-05 |
William Marsh Rice University |
Total synthesis of shishijimicin a and analogs thereof
|
|
IL296285A
(en)
|
2015-07-06 |
2022-11-01 |
Regeneron Pharma |
Multispecific antigen-binding molecules and uses thereof
|
|
EP3365025B1
(en)
|
2015-10-20 |
2020-07-15 |
Genentech, Inc. |
Calicheamicin-antibody-drug conjugates and methods of use
|
|
US20170189548A1
(en)
*
|
2015-11-25 |
2017-07-06 |
Immunogen, Inc. |
Pharmaceutical formulations and methods of use thereof
|
|
AU2016359230B2
(en)
|
2015-11-25 |
2020-04-23 |
Ligachem Biosciences Inc. |
Conjugates comprising self-immolative groups and methods related thereto
|
|
MA43416A
(fr)
|
2015-12-11 |
2018-10-17 |
Regeneron Pharma |
Méthodes pour ralentir ou empêcher la croissance de tumeurs résistantes au blocage de l'egfr et/ou d'erbb3
|
|
BR112018014759B1
(pt)
|
2016-01-25 |
2024-02-27 |
Regeneron Pharmaceuticals, Inc |
Compostos derivados de maitasinoide e seus conjugados, composição compreendendo os mesmos, seus métodos de fabricação e uso
|
|
WO2017160954A1
(en)
|
2016-03-15 |
2017-09-21 |
Seattle Genetics, Inc. |
Combinations of pbd-based antibody drug conjugates with bcl-2 inhibitors
|
|
CN105726527B
(zh)
*
|
2016-03-25 |
2018-05-11 |
苏州大学 |
小分子化合物的用途及其组合物
|
|
EP3448891A1
(en)
|
2016-04-28 |
2019-03-06 |
Regeneron Pharmaceuticals, Inc. |
Methods of making multispecific antigen-binding molecules
|
|
WO2017210621A1
(en)
|
2016-06-03 |
2017-12-07 |
Seattle Genetics, Inc. |
Combination of cd33 antibody drug conjugates with chemotherapeutic agents
|
|
WO2017214433A1
(en)
|
2016-06-09 |
2017-12-14 |
Seattle Genetics, Inc. |
Combinations of pbd-based antibody drug conjugates with flt3 inhibitors
|
|
EP3478324A1
(en)
|
2016-07-01 |
2019-05-08 |
GlaxoSmithKline Intellectual Property (No.2) Limited |
Antibody-drug conjugates and therapeutic methods using the same
|
|
JP7066690B2
(ja)
|
2016-09-23 |
2022-05-13 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
抗ｍｕｃ１６（ムチン１６）抗体
|
|
MY199468A
(en)
|
2016-09-23 |
2023-10-31 |
Regeneron Pharma |
Anti-steap2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind steap2 and cd3, and uses thereof
|
|
ES3046537T3
(en)
|
2016-11-08 |
2025-12-02 |
Regeneron Pharma |
Steroids and protein-conjugates thereof
|
|
TWI782930B
(zh)
|
2016-11-16 |
2022-11-11 |
美商再生元醫藥公司 |
抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
|
|
KR102085798B1
(ko)
|
2016-12-28 |
2020-03-06 |
주식회사 인투셀 |
베타-갈락토사이드가 도입된 자가-희생 기를 포함하는 화합물
|
|
KR20200007905A
(ko)
|
2017-05-18 |
2020-01-22 |
리제너론 파마슈티칼스 인코포레이티드 |
사이클로덱스트린 단백질 약물 접합체
|
|
WO2018213082A1
(en)
|
2017-05-18 |
2018-11-22 |
Regeneron Pharmaceuticals, Inc. |
Bis-octahydrophenanthrene carboxamides and protein conjugates thereof
|
|
DK3635009T3
(da)
|
2017-06-07 |
2026-03-30 |
Regeneron Pharma |
Sammensætninger og fremgangsmåder til internalisering af enzymer
|
|
MX2020004691A
(es)
|
2017-11-07 |
2020-08-20 |
Regeneron Pharma |
Enlazadores hidrofilicos para conjugados anticuerpo-farmaco.
|
|
SG11202006510XA
(en)
|
2018-01-08 |
2020-08-28 |
Regeneron Pharma |
Steroids and antibody-conjugates thereof
|
|
KR102871690B1
(ko)
|
2018-04-30 |
2025-10-16 |
리제너론 파마슈티칼스 인코포레이티드 |
Her2 및/또는 aplp2에 결합하는 항체 및 이중특이적 항원-결합 분자 및 접합체 그리고 이들의 용도
|
|
CN118955710A
(zh)
|
2018-05-09 |
2024-11-15 |
里珍纳龙药品有限公司 |
抗msr1抗体及其使用方法
|
|
BR112020023145A2
(pt)
|
2018-05-17 |
2021-02-02 |
Regeneron Pharmaceuticals, Inc. |
anticorpo anti-cd63 ou fragmento de ligação ao antígeno do mesmo, molécula de ligação ao antígeno biespecífica, proteína terapêutica de múltiplos domínios, polinucleotídeo composição farmacêutica, e, composto
|
|
PL3710485T3
(pl)
*
|
2018-05-30 |
2021-09-13 |
Abbvie Stemcentrx Llc |
Koniugaty lek-przeciwciało anty-sez6 i sposoby ich stosowania
|
|
IL283313B2
(en)
|
2018-11-20 |
2025-08-01 |
Regeneron Pharma |
Bis-octahydrophenanthrene carboxamide derivatives and protein conjugates thereof for use as lxr agonists
|
|
JP7590328B2
(ja)
|
2018-12-21 |
2024-11-26 |
レゲネロン ファーマシューティカルス，インコーポレーテッド |
ツブリシン及びタンパク質－ツブリシンコンジュゲート
|
|
PH12021551476A1
(en)
|
2018-12-21 |
2022-04-25 |
Regeneron Pharma |
Rifamycin analogs and antibody-drug conjugates thereof
|
|
BR112021013464A2
(pt)
|
2019-01-08 |
2021-09-21 |
Regeneron Pharmaceuticals, Inc. |
Ligantes sem traço e conjugados de proteína dos mesmos
|
|
CN120241997A
(zh)
|
2019-02-18 |
2025-07-04 |
伊莱利利公司 |
治疗性抗体制剂
|
|
CA3128519A1
(en)
|
2019-02-21 |
2020-08-27 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating ocular cancer using anti-met antibodies and bispecific antigen binding molecules that bind met
|
|
JP2022530482A
(ja)
|
2019-05-02 |
2022-06-29 |
レゴケム バイオサイエンシズ， インク． |
トリス構造を有するリンカーを含むリガンド―薬物複合体
|
|
GB201910899D0
(en)
*
|
2019-07-31 |
2019-09-11 |
Scancell Ltd |
Binding members
|
|
AU2020349462A1
(en)
|
2019-09-16 |
2022-03-03 |
Regeneron Pharmaceuticals, Inc. |
Radiolabeled MET binding proteins for immuno-PET imaging
|
|
US11814428B2
(en)
|
2019-09-19 |
2023-11-14 |
Regeneron Pharmaceuticals, Inc. |
Anti-PTCRA antibody-drug conjugates and uses thereof
|
|
JP2023511956A
(ja)
|
2020-01-24 |
2023-03-23 |
レゲネロン ファーマシューティカルス，インコーポレーテッド |
タンパク質－抗ウイルス化合物コンジュゲート
|
|
KR20220148200A
(ko)
|
2020-02-28 |
2022-11-04 |
리제너론 파마슈티칼스 인코포레이티드 |
Her2에 결합하는 이중특이적 항원 결합 분자 및 이의 사용 방법
|
|
CN115968304A
(zh)
|
2020-04-16 |
2023-04-14 |
瑞泽恩制药公司 |
狄尔斯-阿尔德缀合方法
|
|
WO2021262910A2
(en)
|
2020-06-24 |
2021-12-30 |
Regeneron Pharmaceuticals, Inc. |
Tubulysins and protein-tubulysin conjugates
|
|
CN116390771A
(zh)
|
2020-07-13 |
2023-07-04 |
瑞泽恩制药公司 |
与蛋白中的谷氨酰胺残基缀合的喜树碱类似物及其用途
|
|
CA3191304A1
(en)
|
2020-09-14 |
2022-03-17 |
Amy Han |
Antibody-drug conjugates comprising glp1 peptidomimetics and uses thereof
|
|
JP2023541133A
(ja)
*
|
2020-09-14 |
2023-09-28 |
アムジエン・インコーポレーテツド |
凍結乾燥タンパク質製剤を作製する方法
|
|
CA3190569A1
(en)
|
2020-10-22 |
2022-04-28 |
Christopher Daly |
Anti-fgfr2 antibodies and methods of use thereof
|
|
EP4000635A1
(en)
*
|
2020-11-16 |
2022-05-25 |
Frank J. Hernandez |
Therapeutic-oligonucleotides activated by nucleases
|
|
CA3220081A1
(en)
|
2021-07-28 |
2023-02-02 |
Thomas Nittoli |
Protein-antiviral compound conjugates
|
|
US20230414775A1
(en)
|
2021-12-29 |
2023-12-28 |
Regeneron Pharmaceuticals, Inc. |
Tubulysins and protein-tubulysin conjugates
|
|
CA3241734A1
(en)
|
2022-01-12 |
2023-07-20 |
Amy Han |
Camptothecin analogs conjugated to a glutamine residue in a protein, and their use
|
|
AU2023208050A1
(en)
|
2022-01-14 |
2024-07-04 |
Regeneron Pharmaceuticals, Inc. |
Verrucarin a derivatives and antibody drug conjugates thereof
|
|
KR20230132640A
(ko)
|
2022-03-04 |
2023-09-15 |
앱티스 주식회사 |
티올 반응성 에디티브를 이용한 항체-약물 컨쥬게이트의 제조 수율을 높이는 방법
|
|
JP2025512735A
(ja)
|
2022-03-11 |
2025-04-22 |
リジェネロン ファーマシューティカルズ，インク． |
Ｇｌｐ１ペプチド模倣体を含む抗ｇｌｐ１ｒ抗体係留型薬物コンジュゲートおよびその使用
|
|
AU2023297610A1
(en)
|
2022-06-27 |
2025-01-09 |
Trioar, Inc. |
Novel linker compound and ligand-drug conjugate therefor
|
|
JP2025525296A
(ja)
|
2022-06-27 |
2025-08-05 |
トライオール インコーポレイテッド |
自壊性基を含む化合物及びそれを含むリガンド－薬物コンジュゲート
|
|
CN120239705A
(zh)
|
2022-07-21 |
2025-07-01 |
萤火虫生物股份有限公司 |
糖皮质激素受体激动剂和其缀合物
|
|
KR20240125071A
(ko)
|
2022-11-01 |
2024-08-19 |
앱티스 주식회사 |
Fc 결합성 유닛을 포함하는 화합물 및 이를 이용하여 제조된 컨쥬게이트
|
|
WO2024118785A2
(en)
|
2022-11-30 |
2024-06-06 |
Regeneron Pharmaceuticals, Inc. |
Tlr7 agonists and antibody-drug-conjugates thereof
|
|
WO2024138000A1
(en)
|
2022-12-21 |
2024-06-27 |
Regeneron Pharmaceuticals, Inc. |
Prodrugs of topoisomerase i inhibitor for adc conjugations and methods of use thereof
|
|
WO2024168199A1
(en)
|
2023-02-09 |
2024-08-15 |
Regeneron Pharmaceuticals, Inc. |
Antibody-drug conjugates via inverse electron demand diels-alder reactions
|
|
WO2024229105A1
(en)
|
2023-05-02 |
2024-11-07 |
Regeneron Pharmaceuticals, Inc. |
Anti-human m-cadherin (cdh15) antibodies, conjugates, and uses thereof for delivery of genetic payloads to muscle cells
|
|
CN121568720A
(zh)
|
2023-07-10 |
2026-02-24 |
瑞泽恩制药公司 |
抗人类cacng1抗体-药物缀合物及其用途
|
|
US20250171516A1
(en)
|
2023-11-03 |
2025-05-29 |
Regeneron Pharmaceuticals, Inc. |
Peptide acids as a glp1r agonist and antibody-drug conjugates thereof
|
|
WO2025117727A1
(en)
|
2023-11-29 |
2025-06-05 |
Regeneron Pharmaceuticals, Inc. |
Analogs of quinoxaline/quinoline cytotoxins, linker- payloads, protein-drug conjugates, and uses thereof
|
|
US20260078179A1
(en)
|
2024-07-18 |
2026-03-19 |
Novarock Biotherapeutics, Ltd. |
Cdh17 antibodies and uses thereof
|